Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Growing evidence suggests that patients with cancer have better responses to the Moderna COVID-19 vaccine than to the Pfizer-BioNTech vaccine.
Women in academic medicine typically have lower starting salaries than men, and this disparity remains after 10 years on the job.
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
An update to active surveillance recommendations has some physicians concerned.
About 20% of pediatric cancer patients who developed COVID-19 had severe or critical disease.
Responses varied according to patients’ cancer type, the anticancer treatment they received, and which vaccine was used.
Integrating molecular profiling into current clinical stratification could improve outcomes in rhabdomyosarcoma, according to researchers.
Children treated for neuroblastoma developed myeloid neoplasms with specific platinum chemotherapy-associated mutation signatures.